CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech unit controlled by the Li Ka-shing family.
The agreement paved the way for TransCode to acquire the parent company of Polynoma from DEFJ, an indirect wholly owned unit of CK Life, the latter said in a filing with the Hong Kong stock exchange after trading hours on Wednesday.
